Ejaculatory function · men with benign prostatic hyperplasia
1 finding from 1 review
All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Recurrent venous thromboembolism (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in major bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).
1 finding from 1 review
Thrombocytopenia (main analysis‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in thrombocytopenia (main analysis‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Intervention not reported
Post‐immunotherapy treatment response · ovarian carcinoma
1 finding from 1 review
Diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy)
It is very uncertain whether probiotics changes any diarrhoea compared with other active treatment (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · participants with cancer treated with radiotherapy (with or without chemotherapy)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade ≥ 3 diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy)
Probiotics may leads to lower severity of diarrhoea: grade 3 or higher compared with other active treatment (low certainty).
1 finding from 1 review
Time to rescue medication ‐ not measured · participants with cancer treated with radiotherapy (with or without chemotherapy)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Requiring rescue medication for diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy)
It is very uncertain whether probiotics changes requiring rescue medication for diarrhoea compared with other active treatment (very low certainty).
1 finding from 1 review
Adverse events · participants with cancer treated with radiotherapy (with or without chemotherapy)
1 finding from 1 review
All‐cause mortality · participants with cancer treated with radiotherapy (with or without chemotherapy)
1 finding from 1 review
Refractive error ‐ very high myopia ‐ at 30 months of age (unit of analysis: eyes) · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy may leads to lower refractive error ‐ very high myopia ‐ at 30 months of age (unit of… compared with conventional laser/cryotherapy (low certainty).
1 finding from 1 review
All‐cause mortality Up to 28 days following admission · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 28 days following admission compared with inactive Control (moderate certainty).
1 finding from 1 review
Arterial thrombotic events ‐ up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Prophylactic trials: intervention showed no clear difference in arterial thrombotic events Up to 30 days post‐operatively compared with inactive control (low certainty).
2 findings from 1 review
Venous thrombotic events Up to 4 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Arterial thromboembolic events at 1 to 2 years · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Arterial thromboembolic events ‐ Duration of hospital stay (whole population) · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review